Skip to main
MDT
MDT logo

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 41 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 39%
Sell 0%
Strong Sell 2%

Bulls say

Medtronic's stock outlook remains positive due to strong growth in its neuromodulation and diabetes segments, with reported revenue growth in the low double digits driven by the increasing adoption of the MiniMed 780G AID system. The company's forecast for FY25 indicates a projected revenue increase of 4.75-5.00% along with EPS growth of 10-11% year-over-year, signaling robust financial performance independent of foreign exchange fluctuations. Additionally, improvements in non-GAAP gross and operating margins further enhance the financial profile, reflecting operational efficiency and favorable market conditions in key therapeutic areas.

Bears say

Medtronic's outlook appears negative primarily due to anticipated slowing revenue growth, projected to decline to low single digits amidst unsuccessful new product launches and market share losses, particularly in key product categories. Additionally, the company's operating margins are likely to remain flat or deteriorate, contributing to earnings that fall below market consensus. Ongoing risks, including competitive pressures, disappointing sales from new product segments, and adverse foreign currency impacts, further underscore the potential for continued financial challenges, as evidenced by recent sales misses and a decline in Medical Surgical revenues.

Medtronic (MDT) has been analyzed by 41 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 39% suggest Holding, 0% advise Selling, and 2% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 41 analysts, Medtronic (MDT) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.93, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.93, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.